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Human VRK2 modulates apoptosis by interaction with
Bcl-xL and regulation of BAX gene expression
DM Monsalve1,2, T Merced1, IF Ferna´ndez1,2, S Blanco1,3, M Va´zquez-Cedeira1,2 and PA Lazo*,1,2
VRK2 is a novel Ser-Thr kinase whose VRK2A isoform is located in the endoplasmic reticulum and mitochondrial membranes. We
have studied the potential role that VRK2A has in the regulation of mitochondrial-mediated apoptosis. VRK2A can regulate the
intrinsic apoptotic pathway in two different ways. The VRK2A protein directly interacts with Bcl-xL, but not with Bcl-2, Bax, Bad,
PUMA or Binp-3L. VRK2A does not compete with Bax for interaction with Bcl-xL, and these proteins can form a complex that
reduces apoptosis. Thus, high VRK2 levels confer protection against apoptosis. In addition, VRK2 knockdown results in an
increased expression of BAX gene expression that is mediated by its proximal promoter, thus VRK2A behaves as a negative
regulator of BAX. Low levels of VRK2A causes an increase in mitochondrial Bax protein level, leading to an increase in the release
of cytochrome C and caspase activation, detected by PARP processing. VRK2A loss results in an increase in cell death that can be
detected by an increase in annexinVþ cells. Low levels of VRK2A increase cell sensitivity to induction of apoptosis by
chemotherapeutic drugs like camptothecin or doxorubicin. We conclude that VRK2A protein is a novel modulator of apoptosis.
Cell Death and Disease (2013) 4, e513; doi:10.1038/cddis.2013.40; published online 28 February 2013
Subject Category: Experimental Medicine
The intrinsic apoptotic pathway is partly controlled by proteins
present on the mitochondrial membrane. This apoptotic
protein family is defined by the structural characteristics of
its BH (Bcl-2 homology) domains.1 There are four types of BH
domains and their combination determine the interaction of
these proteins;2–4 some are anti-apoptotic, such as Bcl-2 and
Bcl-xL, or pro-apoptotic, such as Bax.2,3,5,6 Others only have a
unique BH3 domain and are subdivided in activators of
proapoptotic proteins, such as Bid, or inhibitors of anti-
apoptotic proteins, such as PUMAa, Bad or Bnip3L. These
proteins also have a transmembrane domain in their
C-terminal region. The activation of the apoptotic signal
activates the translocation of cytosolic Bax to the
outer mitochondrial membrane and induces the release of
cytochrome c.7
Apoptosis is further controlled by the interaction of these BH
proteins with other cellular proteins. In Epstein–Barr virus-
infected cells, the BHRF1 protein, a viral homologue of
mammalian Bcl-2, has a protective role against apoptosis.8
This protective role detected in infected cells is mediated by
the direct interaction between viral BHRF1 and cellular
VRK2A.8,9 Thus, apoptosis is also modulated by additional
cellular proteins which in general are not known. Based on this
observation, we hypothesized that VRK2A might have a
protective role against apoptosis if it could interact with, and
regulate, proteins that participate in the mechanisms that
trigger or execute apoptosis in human cells.
The VRK (vaccinia-related kinase) family of protein kinases
forms a divergent branch in the human kinome,10 composed
of three members,11 but only two of them, VRK112 and
VRK213 are catalytically active kinases. These proteins
present sequence and structural differences in their kinase
domain with respect to most kinases, and have an unrelated
C-terminal region.13,14 Their activity can be regulated by
protein–protein interactions, such as interaction with the small
GTPase Ran15 or histones.16 VRK1 is a nuclear protein
implicated in cell cycle regulation17 that behaves like an early
gene,18,19 and also participates in additional processes such
as DNA-damage responses,20 Golgi fragmentation,21 nuclear
envelope dynamics9 and chromatin condensation.17 Among
its phosphorylation targets are transcription factors such as
p53,12 c-Jun,22 ATF223 and CREB.19
The VRK2 protein has two isoforms generated by alter-
native splicing.24 One of them, VRK2A, also known as
VRK2,13 is the canonical full-length protein and has 508
amino acids with a C-terminus transmembrane domain.13,24
VRK2A is anchored to the endoplasmic reticulum and
mitochondria.24 VRK2B is a shorter isoform that has 397
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amino acids, lacks the transmembrane region and is detected
free in nucleus and cytosol.24 Both isoforms have, in vitro, a
similar pattern of phosphorylation substrates25 and sensitivity
to kinase inhibitors.24,26 Thus, the specificity of their biological
effects is most likely determined by their subcellular localiza-
tion and the proteins present in their local microenvironment.
VRK2A anchored to the endoplasmic reticulum is able to
modulate cellular responses mediated by MAPK signalling
pathways.27–30 VRK2A directly interacts with the JIP1 scaffold
protein, forming signalosomeswith a very highmolecular size,
41000 kDa.27,28 The inclusion of VRK2A in these complexes
prevents the phosphorylation of c-Jun in response to
hypoxia27 or interleukin-1b.28 Mechanistically, the interaction
between VRK2A and JIP1 prevents the incorporation of JNK
(c-Jun N-terminal kinase) to the complex, thus c-Jun cannot
be phosphorylated. Reduction in VRK2A levels results in an
increased responsemediated by this pathway.27,28 Moreover,
VRK2 can form a macromolecular complex by interacting with
the KSR1 scaffold protein and this interaction reduces
signalling mediated by MAPK in response to ErbB2 in breast
cancer,29,30 and to activated oncogenes such as Ras and
B-Raf29 mutants. A subpopulation of VRK2A was also
identified located on the mitochondrial membrane,24 but no
function is known to be associated to its presence on this
organelle. Therefore, we tested whether this VRK2A sub-
population was able to affect the intrinsic apoptotic pathway,31
which is mediated by mitochondria.31 In this study, it has been
identified that VRK2A levels can modulate apoptosis in two
different ways, by its interaction with Bcl-xL and by regulation
of BAX gene expression.
Results
VRK2A colocalized with Bcl-xL, Bcl-2 and Bax, but only
interacted with Bcl-xL. The subcellular localization of
proteins can determine their role in specific biological
functions. Although most of the VRK2 isoform A (full-length
protein) is anchored to the endoplasmic reticulum mem-
brane, a minor VRK2A subpopulation is located in the
mitochondria,24 suggesting that this VRK2A subpopulation
might participate in the regulation of cellular functions
mediated by mitochondria, as is the case with the intrinsic
apoptotic pathway.7 Based on the interaction between
VRK2A and the Epstein–Barr virus BHRF1 protein, a viral
homologue of anti-apoptotic Bcl-2 that interacts with Bcl-2,8 it
is a possibility that VRK2A might also have effects probably
mediated by an interaction between VRK2A and apoptotic
proteins of the Bcl-2 family, of which, Bcl-xL is the
antiapoptotic protein expressed in most cell types. Initially,
it was tested if VRK2A could colocalize with any of the
proteins that participate in apoptosis. Endogenous VRK2A
showed an overlapping confocal immunofluorescence signal
with Bcl-xL (Figure 1a), and with the proapoptotic Bax
(Figure 1b), suggesting that they are physically proximal, but
this does not mean that they are directly interacting.
Next, it was determined if there was a direct association
between these proteins. For this aim, cells were transfected
with GST-VRK2A, and the associated endogenous proteins
were brought down in pulldown assays and identified in
immunoblots. Only endogenous Bcl-xL, but not Bcl-2 or Bax,
interacted with VRK2A (Figure1c). The interaction region was
mapped to the C-terminus of VRK2A between residues
397–508, located between the kinase domain and the
membrane anchor region (Figure 1d), according with the
VRK2 region interacting with Epstein–Barr BHRF1 protein.8
Moreover, an additional, and weaker, interacting region was
identified, which was also detected between residues 1–320
of VRK2A (Figure 1d), but this region containing part of the
kinase domain is not correctly folded.14 The interaction with
Bcl-xL was also detected with kinase-dead VRK2 (K179E)
protein (not shown), and thus it was independent of VRK2
kinase activity.
The potential interaction of VRK2A with BH3-only proteins,
such as PUMAa, BAD and Binp3L was ruled out using a
similar approach (Supplementary Figure S1).
Bax did not directly interact with VRK2A, but it was
present in VRK2A–Bcl-xL complexes. One possible con-
sequence of the interaction between VRK2A and Bcl-xL is
that it might interfere with the formation of the Bcl-xL–Bax
complex. To determine the effect on the different interac-
tions, each of the components was varied in the presence of
saturating amounts of the other proteins. When Bax was
increased, the amount of Bax detected in the GST-VRK2A
pulldown increased accordingly (Figure 2a). These data
indicated that a fraction of the VRK2A–Bcl-xL complex was
able to incorporate Bax. Moreover, increasing amounts of
Bcl-xL resulted in an increase in its presence in the GST-
VRK2A pulldown (Figure 2b), indicating that Bcl-xL was
necessary to form this three-protein complex, and was the
likely bridge between the other two proteins. Bax was
always present in the complex and did not increase,
suggesting that its interaction was not facilitated by the
presence of VRK2A, and indicating that the maximum effect
was already reached (Figure 2a). When saturating amounts
of Bcl-xL and Bax were used, and VRK2 was increased,
there was more VRK2A bound to the complex at the higher
concentrations, suggesting that saturation was already
reached (Figure 2c), and that a ternary complex was being
formed. From these data, it could be concluded that VRK2A
forms a complex with these two proteins without competition
for their interaction.
To determine if VRK2A was able to phosphorylate
either Bcl-xL or Bax, different in vitro kinase assays were
performed. VRK2A did not phosphorylate any of these
proteins (not shown).
VRK2 regulated the expression of BAX gene. One
mechanism by which VRK2 might regulate apoptosis is by
regulating, directly or indirectly, the expression of BAX, which
is essential for triggering apoptosis. Therefore, it was first
tested if the level of Bax protein was affected by the
knockdown of VRK2. VRK2 knockdown resulted in an
increase in Bax protein levels, both total protein recognized
by antibody 2D2, and activated Bax recognized by antibody
6A7 (Figure 3a), suggesting that VRK2A protein had a
negative effect on Bax expression or stability. Furthermore, a
reduction in the levels of anti-apoptotic proteins Bcl-2 and
Bcl-xL was detected when VRK2 was knocked down,
suggesting a role of VRK2 in protecting cells from apoptosis.
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To determine if the effect on Bax protein levels was a
consequence of an effect mediated by regulation of BAX
gene expression, the level of BAX mRNA was determined by
qt-RT-PCR. Loss of VRK2 using two different siRNAs resulted
in a significant increase in the expression of BAX mRNA
(Figure 3b). Therefore, this result indicated that VRK2
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Figure 1 Subcellular localization and interactions of VRK2A with apoptotic proteins. (a) Colocalization of endogenous VRK2 with transfected Bcl-xL detected by confocal
microscopy in A549 cells. VRK2 was detected with a rabbit polyclonal antibody and Bcl-xL with a monoclonal antibody. (b) Colocalization of VRK2 with transfected Bax
detected by confocal microscopy in A549 cells. Bax was detected with a monoclonal antibody. (c) Detection of interaction between VRK2 and Bcl-xL, Bcl-2 or Bax in pulldown
assays. HeLa cells were transfected with plasmid pCEFL-GST-VRK2A that expresses GST-VRK2A and used in a pulldown assay in which the associated protein were
detected in immunoblots using specific antibodies for GST that detects transfected GST and GST-VRK2, and specific antibodies for detection of endogenous Bcl-2, Bcl-xL or
Bax. The ratio of GST-VRK2/actin ranges between 0.72–0.66 in the three bots. The ration of Bcl-xL/actin is 1.50, and the ratio Bax/actin is 1.40, respectively.(d) Mapping the
interaction between VRK2A and Bcl-xL. The region of interaction between VRK2A and Bcl-xL was performed by pulldown assays with different constructs of the VRK2A
protein, which is summarized in a diagram to the right. VRK2B is a spliced variant that has 397 aminoa cids and is identical to the N-terminal region of VRK2A
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inhibited BAX gene expression. BCL2 and Bcl-xl mRNA levels
were also analysed , but no differences in gene expression
were detected after VRK2 knockdown (not shown).
Next, it was tested if the effect of VRK2 was mediated by
regulation of the BAX gene promoter. VRK2 was knocked
down in A549 cells with two different siVRK2 oligonucleotides
followed by transfection with a proximal BAX promoter–
luciferase construct, pGL-3-Bax-Luc (–687 to –318), and the
effect on luciferase expression was determined. VRK2
knockdown with two different siVRK2, –06 and –08, resulted
in six- and eight-fold induction of luciferase expression
controlled by the proximal BAX gene promoter respectively
(Figure 3c). These results indicated that VRK2 protein
negatively regulated BAX gene expression. Next, as BAX
gene expression can be activated by treatment with camp-
tothecin,32 it was tested if overexpression of VRK2A was able
to prevent this activation of Bax. For this aim, the BAX
promoter was activated by treating A549 cells with 5mM
camptothecin, and a significant inhibition of the Bax promoter
was observed in cells in which VRK2A was overexpressed
(Figure 3d), but Bax promoter was not affected by VRK1
(Figure 3d). All these data indicated that VRK2A inhibited
transcription directed by the BAX gene promoter.
Loss of VRK2A induced a release of cytochrome c and
PARP processing. A subpopulation of the cytosolic VRK2A
protein is located in the mitochondria,24 a central organelle in
the intrinsic apoptotic pathway. First, the effectiveness of
VRK2 knockdown was determined in two lung cancer cell
lines, H1299 (p53 / ) and A549 (p53þ /þ ), and in HeLa
cells. VRK2A knockdown at protein level was achieved in the
three cell lines with two different siRNA, si-VRK2-06
(Figure 4a) and si-VRK2-M (Supplementary Figure S2). In
cell culture, these effects of siVRK2 were manifested as a
reduction in cell number (not shown), which could be due to
the induction of cell death.
To establish if indeed the loss of VRK2A was having an
effect on the intrinsic apoptotic pathway, the release of
mitochondrial cytochrome c and its redistribution in cytosolic
and membrane fractions was determined, which is a likely
consequence of the effect of VRK2A on Bax. VRK2A
knockdown with siVRK2-06 resulted in a significant increase
of cytochrome c released into the soluble cytosolic fraction,
accompanied by a reduction in its mitochondrial level
(Figure 4b, top gel). A similar result was also observed using
a different siRNA (siVRK2-M) (Supplementary Figure S2).The
release of cytochrome c should activate caspases that could
be detected by processing of PARP. VRK2 knockdown
resulted in an increase in the detection of the 85-kDa PARP
processed by caspase 9 (Figure 4c). These results indicated
that loss of VRK2A facilitated induction of the intrinsic
apoptotic pathway and we concluded that high levels of
VRK2A have a protective role as inhibitors of apoptosis.
Loss of VRK2 sensitized cells to treatment with
camptothecin. The increase in apoptosis as a conse-
quence of reduced levels of VRK2 suggested that cells
might become more sensitive to chemotherapy. Therefore, it
was studied if elimination of VRK2 made cells more
responsive to apoptosis induced by camptothecin, a current
drug used in chemotherapy whose mechanism is based on
induction of DNA damage. Initiation of apoptosis requires the
translocation of Bax to the mitochondrial membrane and
release of cytochrome c. The distribution of cytochrome c
and pro-apoptotic Bax was determined by fractionation of
cytosolic and membrane fractions. VRK2 was knocked down
in HeLa cells and these cells were treated with camptothecin.
In cells in which VRK2 was knocked down, there was an
increase in cytosolic cytochrome c. Membrane-bound Bax
appeared much earlier in siVRK2-knocked down cells than
si-control-treated cells and at 3 hours, the differences were
clearly detectable. (Figure 5a). After 6 hours of camptothecin
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Figure 2 Formation of a complex between VRK2A, Bcl-xL and Bax detected in pulldown assays. (a) Effect of increasing Bax in the presence of saturating amounts of
VRK2A and Bcl-xL. (b) Effect of increasing Bcl-xL in the presence of saturating VRK2A and Bax. (c) Effect of increasing VRK2A in the presence of saturating Bcl-xL and Bax.
HEK293T cells were transfected with the indicated amounts of plasmids pCEFL-GST-VRK2A, p8-AU1-Bax and p8-Bcl-xL. As a negative control, pCEFL-GST was used. Forty-
eight hours after transfection, a GST pulldown was performed. The proteins in the input lysates are shown at the top. The proteins present in the pulldown are shown at the
bottom and were detected with the corresponding specific antibody
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treatment, there was no cytochrome c in the membrane
fraction and there was an increase in mitochondrial Bax in
the membrane fraction in those cells in which VRK2 was
knocked down with respect to the control (Figure 5a). This
observation suggested that loss of VRK2 facilitates Bax
translocation to mitochondria and subsequent release of
cytochrome c, accelerating induction of apoptosis induced by
camptothecin.
This result indicated that loss of VRK2 could be promoting
induction of cell death by camptothecin. To further establish
that reduced VRK2 levels were inducing apoptosis, the effect
of siControl or two different si-VRK2 in cells treated with
camptothecin was detected by determination of PARP
processing. VRK2 knockdown by si-VRK2-06 (Figure 5b,
top panel) or si-VRK2-M (Figure 5b, bottom panel) made cells
more sensitive to induction of apoptosis as shown by the loss
of the 116-kDa PARP, which is fully processed at 6 hours of
camptothecin treatment (Figure 5b), and was accompanied
by the appearance of the 85-kDa processed form of PARP.
PARP is a protein implicated in DNA repair, and its inactivation
should be reflected by an increase in cellular DNA damage.
The effect of VRK2 knockdown on the response to camp-
tothecin was analysed in a tunnel assay. Cells with low levels
of VRK2 were positive to DNA damage in the tunnel assay
much earlier than siControl cells (Figure 5c).
Loss of VRK2 promoted cell death. All these results
indicated that cells were more sensitive to the induction of
cell death if VRK2 levels were low. To confirm this possibility,
it was first tested if there were early signs of apoptosis in
A549 cells in which VRK2 was knocked down. In these cells,
there was a very noticeable increase in annexin Vþ cell
positivity at 6 hours of camptothecin treatment, suggesting
that the plasma membrane was already altered (Figure 6a),
which was also manifested by the increase in nonviable cells
detected by uptake of trypan blue (Figure 6b). The alteration
of the mitochondrial electron transport and membrane
potential as a consequence of initiation of apoptosis could
be detected by the uptake and fluorescence of DiOC6 (3).
The VRK2 knockdown resulted in a reduction in DiOC6
fluorescence after camptothecin treatment (Figure 6c). More-
over, A549 cells in which VRK2A was knocked down were
much more sensitive to DNA fractionation induced by
camptothecin treatment, and detected by propidium iodide
staining (Figure 6d). Similar results were obtained in H1299
cells and by treatment with other drugs, such as doxorubicin
or etoposide (not shown). These results led to the conclusion
that reduction of VRK2 levels results in an increased
sensitivity to cell death induced by chemotherapeutic drugs.
Discussion
Apoptosis is a tightly regulated process in which many of the
components that modulate this form of cell death are still
unknown. Regulation of apoptosis can be achieved by
multiple mechanisms, but there are likely two major types.
One is by novel proteins that form a complex with apoptotic or
antiapoptotic proteins, modulating their function. The other is
by regulating the expression of apoptotic or anti-apoptotic
genes and altering their intracellular levels. In the intrinsic
apoptotic pathway, there is an alteration in mitochondrial
membrane, and it is likely that other mitochondrial membrane
protein complexes remain to be identified, but they can
modulate the magnitude of the apoptotic response, and VRK2
could be one of them.
The protective effect observed on apoptosis is partly a
consequence of VRK2A interaction with Bcl-xL, which is
functionally similar to its interaction with the EBV viral
homologue of Bcl-2 and BHRF1.8 Both proteins, Bcl-xL and
BHRF1, interact with the same C-terminal region of VRK2A.8
However, these interactions do not rule out an effect
of phosphorylation mediated by VRK2A, particularly if
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Figure 3 VRK2 regulated BAX expression. (a) VRK2 knockdown in A549 cells
modified Bax protein levels. Si-Ct: Si-Control. The total Bax protein was detected
with the 2D2 antibody, and activated Bax with 6A7 antibody. Moreover, a reduction
in the levels of antiapoptotic proteins, Bcl-xL and Bcl-2 was detected in
immunoblots. (b) VRK2 knockdown increased the level of BAX gene expression
in A549 cells determined by qt-RT-PCR. A549 cells were mock transfected or
transfected with the indicated SiRNA and 3 days after transfection, total RNA was
extracted and the level of Bax and GAPDH mRNA levels were determined by
qt-RT-PCR. The results from four independent experiments are shown. *Po0.05,
**Po0.005, ***Po0.0005. (c) Reduction of VRK2A levels activated expression
from the promoter of BAX. A549 cells were transfected with si-Control (Si-Ct) or two
different si-VRK2 (06 and 08, and 24 hours later, cells were transfected with 1mg of
pGL3-Bax-Luc (–687 to –318) and cells extracts were used to measure the
luciferase activity. The results are the mean of three independent experiments and
the mean with the standard deviation is shown. **Po0.005, ***Po0.0005. (d)
VRK2A overexpression inhibited expression directed by the BAX gene promoter
that is induced in response to camptothecin. A549 cells were treated for 6 hours with
5mM camptothecin followed by transfection with 1mg of empty vector (pCEFL-HA)
or plasmid expressing VRK2A (pCEFL-HA-VRK2A) or VRK1 (pCEFL-HA-VRK1)
together with the reporter pGL3-Bax-Luc. The mean and S.D. from three
independent experiments is shown. ***Po0.0005
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phosphorylations take place as a part of a larger protein
complex, which may include Bax among other components.
As phosphorylation events are known to modulate apoptosis,
phosphorylation of Bax in Ser184, probably by Akt, inhibits
effects of Bax in mitochondria and prevents the induction of
apoptosis.33 The VRK2 knockdown does not affect the Akt
activation.29 Bax is also phosphorylated by JNK in Ser167,
and this phosphorylation is necessary for Bax activation and
translocation to mitochondria.34 VRK2A does not phosphor-
ylate Bax, but it is possible that VRK2A in the mitochondrial
membrane complexmight phosphorylate some protein not yet
identified. This might either interfere with Bax incorporation or
alternatively alter mitochondrial membranes, facilitating its
permeability and cytochrome c release.
Variations in intracellular VRK2A protein levels, either by
knockdown or overexpression, also affect the levels of Bax.
This effect is mediated by the regulation of the BAX promoter
by VRK2A, functioning as a negative regulator of this
promoter. The VRK2A function as a transcriptional repressor
opens up a new aspect in the role of VRK2 as a regulator of
transcription. Thus, VRK2A is acting at two different levels in
the modulation of the cell response to induction of apoptosis:
protein–protein interaction and transcriptional regulation.
The effects of VRK2A observed on cell signalling can also
be influenced by the consequences of other VRK2A protein
interactions. VRK2A interacts with scaffold proteins and
inhibits signal transmission. VRK2A interacts with JIP1, a
JNK scaffold, blocking c-Jun phosphorylation.27,28 VRK2A
also interacts with KSR1 blocking the phosphorylation of ERK,
but has no effect on Akt activation, facilitating cell survival.29
Most of the effects identified by VRK2 are mediated by
protein–protein interaction and theoretically will require the
design of drugs targeting the specific interaction. However,
inhibition of VRK2 activity with kinase inhibitors will affect
signal transduction by a not yet known pathway. The first role
of VRK2 as an active kinase phosphorylating NFAT1 has
been recently reported;35 although VRK2 phosphorylates
some scaffold proteins like JIP-1 (Jun interacting protein 1)
that mediate signals in response to cytokines, such as IL-1b28
or hypoxia,27 but the effect of VRK2 on JIP1 is only dependent
of protein interaction. The field of protein interactions
inhibitors is not developed; although it will permit selective
inhibition of some effects, but not other effects mediated by a
specific protein. In the case of VRK2, induction of its
interaction with Bcl-xL will result in an increase of the
protective effect of Bcl-xL. The structures of VRK214 and
VRK136 indicate that both kinases have a characteristic
catalytic domain that differs from most kinases in several key
residues,10,13 but nevertheless, it is still catalytically
active.12,13,24 These differences in VRK proteins can be
exploited for the development of specific kinase inhibitors.
VRK proteins are likely to have a very low promiscuity,37 and
this is an advantage with respect to other kinases where the
problem of cross inhibition is very high.38,39 VRK2 has a very
low promiscuity index with respect to kinase inhibitors,37,40
and is very insensitive to current kinase inhibitors.41 The
development of VRK2-specific inhibitors might be a potential
mechanism to increase cell sensitivity to current drugs, which
are very toxic.
The effect of VRK2 knockdown on cellular sensitivity to
apoptosis induced by DNA-damaging drugs is unlikely to be
specific. VRK2 knockdown probably sensitizes cells to any
type of stress by reducing the effectiveness of Bcl-xL on
apoptosis protection and thus permitting increased levels and
liberation of Bax. In breast carcinoma, there is an inverse
correlation between the levels of ERBB2 and VRK2, thus,
ERBB2-positive tumours have low VRK2 and curiously, these
tumours are more chemosensitive.29 Breast cancers that are
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ERBB2-negativeandoestrogen receptor-positivehavehigh levels
of VRK2,29 and these tumours are chemoresistant,42,43 probably
by induction of p53- and p21-mediated cell cycle arrest.44
In tumours, high VRK2 levels can have a dual role, on one
side, they might inhibit mitogenic signal-reducing tumour
growth, but on the other hand, they might make cells less
sensitive to apoptosis, contributing to tumour cell survival. The
final effect would be a consequence of the net balance among
alternative signalling pathways and the relative strength of
their respective signals. Thus, high VRK2 levels might be a
component in the formation of more indolent and perhaps,
chemoresistant tumours.
Materials and Methods
Cell culture and flow cytometry. Cell lines A549 (p53 wt) and H1299
(p53 / ) from lung carcinomas, HEK293T cells and HeLa cells were cultured at
37 1C with 5% CO2 in RPMI or DMEM supplemented with 10% heat-inactivated
foetal calf serum supplemented with 2 mM L-glutamine, 50mg/ml streptomycin and
100 U/ml penicillin. All cell lines were purchased from ATCC. For flow cytometry
analysis, cells were fixed with 4% paraformaldehyde and incubated with propidium
iodide. Cells were analysed in a FACScalibur flow cytometer, (Becton Dickinson,
San Jose, CA, USA), data acquisition was performed with Cell Quest programme
(Becton Dickinson), analysed with Modfit LT programme (Verity Software House,
Topsham, ME, USA).
Preparation of cytosolic and membrane subcellular fractions.
Cells were washed twice in cold PBS at 4 1C and 2300 r.p.m in an Eppendorf
5415R centrifuge. The cellular pellet was lysed in a buffer containing 25mM
TrisHCl (pH 6.8), 250mM sucrose, 1 mM EDTA, 0.1 mM benzamidine and 1 mg/ml
each of leupeptin, pepstatin and aprotinin. The suspension was centrifuged at
13000 r.p.m in an Eppendorf 5415R centrifuge for 3 min. The supernatant was
centrifuged at 100 000 g for 1 h at 4 1C and the pellet contained the
endoplasmic reticulum and mitochondrial membranes.21
Chemicals. Camptothecin and propidium iodide were from Sigma (St. Louis,
MO, USA). DiOC6(3) (3,3
0—Dihexyloxacarbocyanine iodide) was from Molecular
Probes (Eugene, OR, USA). Annexin V-FITC was from Immunostep
(Salamanca,Spain).
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Plasmids and transfections. VRK2 was expressed from plasmid pCEFL-
GST-VRK2A, pCEFL-HA-VRK2A, pCEFL-GST-VRK2B and deletion or partial
constructs with regions 1–320, 256–508, 364–508 and 256–397.24,27,28 pCMV-
FLAG-PUMAa was from K Vousden;45 Bax and Bcl-xL were expressed from
plasmids p8-AU1-Bax and p8-Bcl-xL (from F Pimentel).46 Bad from PCDNA3-AU1-
BAD (L del Peso). Bcl-2 from pSFFV-Bcl2 (JL Ferna´ndez-Luna). Empty vector
plasmids, pCEFL-GST and pCEFL-HA, were used as negative controls in
transfections.24 pGL-3-Bax-Luc ( 687 to  318) was from M Oren (Weitzman
Institute, Rehovot, Israel).47 Luciferase assays have been previously reported.24,48
Transfections were performed using JetPEI reagent (Polyplus, Illkirch, France)
according to manufacturer’s instructions and in detail has been previously
published.24,28,29,35,49 The total amount of DNA was kept constant by completion
with the corresponding empty vector.
RNA and qt-RT-PCR. Total RNA was extracted from A549 cells using
RNeasy kit from Qiagen (Valencia, CA, USA). The quality of the extracted RNA
was determined in a Bioanalyzer 2100 nano-lab chip (Agilent, Santa Clara, CA,
USA). For qtRT-PCR, 50 mg of total RNA was amplified with specific primers for
Bax, VRK2 and GAPDH. The Quantitect-SYBR green RT-PCR kit (Qiagen) was
used in an iCycler iQ5 Multicolour Real-time PCR Detection System and Optical
System Software BIO-RAD iQ5 (BioRad, Hercules, CA, USA).
The following primers were used for RT-PCR amplification. The following primers
were used for RT-PCR amplification. Bax was amplified with primers (forward: 50-
GGCCCACCAGCTCTGAGCAGA-30, and reverse: 50-GCCACGTGGGCGTCC
CAAAGT-30). Bcl-xL (forward: 50-TCCTTGTCTACGCTTTCCACG-30; reverse: 50-
GGTCGCATTGTGGCCTTT-30). Bcl-2 (forward: 50-CATGTGTGTGGAGAGCG
TCAA-30 and reverse: 50-GCCGGTTCAGGTACTCAGTCA-30). VRK2 (forward:
50-AGTGAGAGAAGCGCTGAGTCCT-30 and reverse: 50-CAAAGGTTCTTGAGA
CTCTTG-30). GAPDH (forward: 50-GGTCTTACTCCTTGGAGGCCATGTG-30 and
reverse: 50-ACCTAACTACATGGTTTACATGTT-30). All primers were synthesized
by Sigma-Aldrich (St Louis, MO, USA).
VRK2 knockdown. VRK2 knockdown was performed with three different
siRNA. Si-VRK2-06 (target sequence: GCAAGGUUCUGGAUGAUAU) and siVRK2-
08 (target sequence: CACAAUAGGUUAAUCGAAA) from Dharmacon (Chicago, IL,
USA), and si-VRK2-M (target sequence: GATATTGTCCCAATGGGAA) from Mission
series (Sigma, St Louis, MO, USA). Si-Control was from Dharmacon. 160 nM of
si-Control or si-VRK2 was lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA)
according to manufacturer’s instructions. These type of RNA interference have been
previously performed and described in detail for VRK2.24,28,29,35,49
Antibodies. VRK2 was detected with a rabbit polyclonal antibody24,28,29,49 that
recognized both isoforms and was prepared by immunization of a rabbit with
human GST-VRK2A fusion protein. AU1 epitope was detected with monoclonal or
polyclonal antibodies from Covance (Emeryville, CA, USA). GST was detected
with monoclonal B-14 (sc-138, Santa Cruz Biotecnology, Santa Cruz, CA, USA).
HA epitope was detected with monoclonal (Covance) or polyclonal antibody
(eBioscience, San Diego, CA, USA). Flag was detected with polyclonal and
monoclonal antibodies from Sigma. Monoclonal antibodies against Bax (6A7), Bcl-
xL (2H12), cytochrome c (7H8.2C12) and PARP (c2-10) were from BD
Biosciences (San Jose, CA, USA). Cleaved PARP was detected with monoclonal
antibody (F21-852) from BD Biosciences. Rabbit polyclonal anti-Bax was from
Abcam (Cambridge, UK). Bcl-2 was detected with sc-492 from Santa Cruz.
Cytochrome oxidase II was detected with a monoclonal from Invitrogen. b-actin
antibody was from Sigma. The secondary antibodies used from Amersham
Biosciences (GE Healthcare, Buckinghamshire, UK) were anti-mouse-Cy2
(Fluorolink Cy2), anti-rabbit-Cy3 (Fluorolink Cy3) and anti-rabbit-Cy2
(Fluorolink Cy2) in immunofluorescence or anti-mouse-HRP or anti-rabbit-HRP
for western blots.
0
10
20
30
40
50
60
0 3 6 9 hrs
Si-
V2
-06
A549
VRK2
Si-Ct
Si-V2-06
24 48 72
10
20
30
40
50
60
70
Si-V2-06
si-Ct
si-V2-06
12 h 24 h 48 h
100
0
20
40
60
80
0
si-V2-06
si-Ct
Time after Camptothecin (5 μM)
Lo
ss
 o
f D
IO
C
flu
or
es
ce
nc
e 
(%
)
Time
Time after Camptothecin
(5 μM)
72 h24 h 48 h
18 %10 %7 %
20 % 47 % 55 %
β-actin
Si-
Ct
hrs
Time after Camptothecin (5 μM)Time after Camptothecin (5 μM)
An
ne
xi
n 
V 
+ 
(%
)
Si-Ct
D
ea
d 
ce
lls
 (%
)
Figure 6 Effect of VRK2 knockdown on cell death induced by camptothecin treatment. VRK2 was knocked down in A549 cells and after 3 days, cells were treated with
camptothecin for the indicated time points. (a) Effect of VRK2 knockdown on the sensitivity of A549 cells to camptothecin detected by alterations in the plasma membrane with
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Pulldown assays and immunoblotting. Cells were harvested 48 h post
transfection and lysed with a buffer containing 20mM Tris-HCl pH 7.4, 137mM
NaCl, 2 mM EDTA, 25mM b-glycerophosphate, 2mM pyrophosphate, 10% (v/v)
glycerol and 1% Triton X-100 plus protease inhibitors. 50 mg of total protein lysate
were analysed in a 10% SDS–polyacrylamide gel. GST pulldowns were performed
by incubating 1mg of total cell extract with Glutathione-Sepharose 4B beads
(Amersham Biosciences Pharmacia Biotech) for 12 h at 4 1C. Sepharose beads
were washed three times with lysis buffer and analysed by SDS–PAGE following
by western blots with the corresponding antibodies. Luminescence in westerns blot
was developed with an ECL kit (Amersham Biosciences).
Early apoptosis and annnexin V assay. Early apoptotic cells present
phosphatydilserine on their surface and were detected by flow cytometry of cells
labelled with Annexin V-FITC (Immunostep SL, Salamanca, Spain). HeLa, A549
and H1299 cells were grown and transfected with siControl or siVRK2 as indicated
above and 96 hours later, treated with camptothecin (5 mM). At different time
points, 106 cells were washed in PBS and stained with annexin-V-FITC and
propidium iodide in annexin buffer (0,1 M Hepes/NaOH (pH 7.4) 1.4 M NaCl,
25mM CaCl), incubated for 15min, resuspended in 400ml and analysed by flow
cytometry in a FACS Calibur (Becton Dickinson).
Immunofluorescence and TUNEL assay. Colocalization of proteins
was performed by immunofluorescence. Cells were fixed with 3% paraformalde-
hyde and stained with specific antibodies against endogenous proteins. Nuclei
were stained with DAPI (40,60-diamidino-2-fenilindol). Immunofluorescences were
examined in a confocal Zeiss LSM 510 microscope (Zeiss, Jena, Germany) and
images were analysed with LSM Image Browser software (Zeiss).
To perform TUNEL assay, the cells were transfected with siRNA and treated with
camptothecin (5 mM). At different time points, the culture media was removed and
cells were fixed with 4% paraformaldehyde for 15min, washed with cold PBS and
treated with 0.2% Triton-X100 for 5 min. Cells were blocked for 15min in incubation
buffer (200mM potassium cacodylate, 25mM Tris-HCL, 0.2 mM DTT, 0.25mg/ml
BSA, 2.5 mM cobalt hydrochloride) at room temperature. The buffer was changed
and 5 ml per point were added containing 50mM fluorescein-12-dUTP, 100mM
dATP, 10mM Tris-HCL(pH 7.6), 1 mM EDTA for rTdT. Cells were incubated in a
humidified atmosphere in the dark for 1 h at 37 1C. The reaction was finished by
addition of 1ml 20 SSC for 15min and afterwards cells were rinsed in PBS three
times. The coverslips were treated with antifade and examined in a confocal Zeiss
Axioplan2 microscope. Images were analysed using the Openlab 4.0.2 program
(Improvision, Waltham, MA, USA).
Mitochondrial membrane potential determination. To determine
membrane permeabilisation (DCm) DiOC6
3 (yodo 3-30-dihexiloxacarbocianine)
was used.50,51 For this assay, 2 106 A549 cells/ml were seeded in six-well
plates. Cells were transfected with si-Control, siVRK2-06, or siVRK2-M, as
previously reported.21,52 Ninety-six hours later, cells were treated with 5mM and
collected for analysis at several time points up to 72 h after drug treatment. These
cells were washed in PBS and collected by centrifugation at 15 000 r.p.m for
10min. The cell pellet was suspended in PBS containing 20 nM DiOC6 and was
incubated at 26 1C for 20min. Cells were analysed in a FACS-Calibur (Becton
Dickinson) with the Cell Quest and FCS Express V3 programs (De novo software,
Los Angeles, CA, USA).
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FIGURE S1. Interaction of VRK2A and PUMAα, BAD or Bnip3L
proteins. HEK293T cells were transfected with pCEFL-GST-VRK2A and
the plasmid expressing the corresponding apoptotic protein. The expression of
the proteins in lysates is shown (top). Cell lysates were used for pulldown
assays, using GST as control, and the bound protein were detected in western
blots (bottom). None of the three proteins tested, PUMAα, BAD or Bnip3L,
interacted with VRK2A.
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FIGURE S2. Effect of VRK2 knockdown on cytochrome C release. a.
Knock down of VRK2 with si-VRK2-M and si-Control (si-Ct) in three
cell lines, lung carcinomas A549 and H1299 and cervical carcinoma
HeLa. b. Effect of VRK2 knockdown on cytochrome C release in A549
cells. The cytochrome C release was determined by its detection in
cytosolic and mitochondrial fractions in extracts prepared 96 hours after
siRNA transfection. Actin, cytochrome C and cytochrome-C oxidase II
were used as markers for the two fractions, cytosolic and mitochondrial,
respectively. Si-Ct: si-Control, Si-VRK2-M: si-VRK2-M (Mission).
